Insulin Lispro (Admelog, Humalog, Lyumjev)

BNF:
Endocrine
Status:
Do Not Prescribe (DNP), Grey, Green
Decision Date:
None
 

Comments

Prescribe by brand

Admelog (Insulin Lispro biosimilar)

GREEN: 100units/ml - preferred cost-effective brand. (decision date - June 2023)

Humalog (Insulin Lispro) 

GREY: 100units/ml - New patient should consider Admelog as the cost-effective choice. Existing patients on Humalog should continue on treatment until the next clinical review takes place to assess if suitable for switching. (decision date - June 2023)

GREY: 200units/ml* (decision date - October 2017)

Lyumjev (Insulin Lispro)

GREEN: 100units/ml 

GREY: 200units/ml* (Decision date - October 2020) 

Lispro Sanofi (Insulin Lispro biosimilar)

DO NOT PRESCRIBE (DNP): 100units/ml. (Decision based on lack of clarity between biosimilar and originator name and the risk of inadvertent switching)  (Decision date - September 2018)

*See MHRA April 2015, High strength, fixed combination and biosimilar insulin products to minimise the risk of medication error. 

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app